How reliable is pathological complete response (pCR) as an endpoint in rectal cancer clinical trials.

Kundu S, Basu A, Das S, Kundu S

Open source

DOI
10.1016/j.critrevonc.2026.105554
Published
2026 Aug 20
Container
Critical reviews in oncology/hematology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.critrevonc.2026.105554,
  title = {How reliable is pathological complete response (pCR) as an endpoint in rectal cancer clinical trials.},
  author = {Kundu S and Basu A and Das S and Kundu S},
  year = {2026},
  journal = {Critical reviews in oncology/hematology},
  doi = {10.1016/j.critrevonc.2026.105554},
  url = {https://doi.org/10.1016/j.critrevonc.2026.105554}
}

RIS

TY  - JOUR
TI  - How reliable is pathological complete response (pCR) as an endpoint in rectal cancer clinical trials.
AU  - Kundu S
AU  - Basu A
AU  - Das S
AU  - Kundu S
PY  - 2026
JO  - Critical reviews in oncology/hematology
DO  - 10.1016/j.critrevonc.2026.105554
UR  - https://doi.org/10.1016/j.critrevonc.2026.105554
ER  - 

APA

S, K., A, B., S, D., & S, K. (2026). How reliable is pathological complete response (pCR) as an endpoint in rectal cancer clinical trials.. Critical reviews in oncology/hematology. https://doi.org/10.1016/j.critrevonc.2026.105554

Source records